Skip to main content
. 2022 Jan 1;107(1):35–43. doi: 10.3324/haematol.2021.278755

Table 1.

Selected phase II studies evaluating novel agents in patients with relapsed/refractory marginal zone lymphoma. Efficacy data from the publication with longest follow-up reported where available.

graphic file with name 10735.tab1.jpg